Welcome to our dedicated page for Sunshine Biopharma SEC filings (Ticker: SBFM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sunshine Biopharma Inc. filings document the reporting record of a public pharmaceutical company with Canadian generic-drug operations and proprietary oncology and antiviral development programs. Form 8-K disclosures cover operating results, material events, warrant solicitation arrangements, auditor changes, officer transitions and shareholder actions affecting common-stock matters.
Proxy and annual-meeting materials describe board elections, board committees, corporate governance, executive compensation, principal shareholders, related-party transactions, auditor ratification and equity incentive plan matters. The company’s filing record also includes late-filing notices for annual reports and capital-structure disclosures involving outstanding warrants and potential stock-split authority.
L1 Capital Global Opportunities Master Fund, Ltd. reports beneficial ownership of 1,000,000 Common Units of Sunshine Biopharma Inc., representing 5.83% of the class.
The filing states the percentage is based on 16,165,945 Common Units outstanding as referenced from the issuer's prospectus and Form 8-K filings dated May 19, 2026. The filing notes 2,000,000 Series C Warrants exercisable into common stock, which are subject to a 4.99% beneficial ownership limitation. The reporting person is organized in the Cayman Islands and is represented by Directors David Feldman and Joel Arber; the cover signature is by Mr. Feldman.
Sunshine Biopharma Inc. Schedule 13G: Reporting persons led by Michael Bigger reported beneficial ownership of 805,000 shares of Common Stock, equal to 4.73% of 17,005,945 shares outstanding as of the issuer prospectus. The filing states the Reporting Persons sold all their Common Stock as of May 19, 2026.
The filing also lists warrants (Pre-Funded, Series B, Series C) that were subject to 4.99% beneficial ownership limitations and were excluded from the reported beneficial ownership counts.
Sunshine Biopharma Inc. completed a best efforts public unit offering, raising approximately $6.0 million in gross proceeds through 12,000,000 Common Units or Pre-Funded Units priced at $0.50 per Common Unit.
Each unit includes one share of common stock or one Pre-Funded Warrant plus two Series C Warrants, each Series C Warrant exercisable at $0.50 per share for five years. The Pre-Funded Warrants are immediately exercisable at $0.00001 per share until fully exercised. If all Series C Warrants are exercised on a cash basis, the Company could receive up to an additional approximately $12.0 million in gross proceeds.
The Company intends to use net proceeds for general corporate purposes and working capital, supporting its Canadian generic drug portfolio and proprietary programs in liver cancer and SARS-related coronavirus infections.
Sunshine Biopharma Inc. is offering 11,160,000 Common Units and 840,000 Pre-Funded Units in an underwritten placement with an aggregate public offering amount of $6,000,000 at a public offering price of $0.50 per Common Unit (or $0.49999 per Pre-Funded Unit) on a best efforts basis. Each Common Unit consists of one share of common stock and two Series C Warrants; each Pre-Funded Unit consists of one Pre-Funded Warrant and two Series C Warrants.
The prospectus registers the shares issuable upon exercise of the Pre-Funded Warrants and Series C Warrants. The offering contemplates net proceeds of approximately $5.0 million to the company to be used for general corporate purposes, including working capital. Shares outstanding were 5,005,945 as of May 15, 2026 and would be 17,005,945 after this offering assuming exercise of all Pre-Funded Warrants, as stated in the prospectus.
Sunshine Biopharma reported Q1 2026 sales of $8.1 million, down about 9% from $8.9 million a year earlier, mainly due to the termination of certain distribution agreements. Gross profit was $2.2 million with a margin of 27%, versus $2.7 million and 30.7% in Q1 2025.
The company posted a net loss of $1.24 million, slightly wider than the prior-year loss of $1.18 million, or $(0.25) per share on 4.9 million weighted-average shares. Operating expenses fell to $3.6 million from $4.0 million as accounting, consulting, marketing, office and R&D costs declined, partly offset by higher salaries and legal fees.
Cash and equivalents were $6.9 million at March 31, 2026, with total assets of $27.9 million and no debt beyond lease liabilities. Management estimates current cash and operating cash flows can fund the business for about 17 months while it works to grow Nora Pharma’s Canadian generic drug sales and advance two proprietary programs in liver cancer mRNA and a PLpro inhibitor for SARS coronavirus infections.
Sunshine Biopharma Inc. has filed an S-1 to offer up to $6,000,000 of common and pre-funded units, including up to 5,825,242 Common Units and associated Series C warrants, on a best efforts basis through Aegis Capital.
Each Common Unit includes one share of common stock and two Series C Warrants with an initial exercise price of $1.03 per share and a five-year term. Alternative Pre-Funded Units substitute a nearly fully paid pre-funded warrant for the common share to help certain investors stay below 4.99% or 9.99% ownership caps. The company estimates net proceeds of about $5.0 million, to be used for general corporate purposes and working capital.
Shares outstanding are expected to increase from 5,005,945 as of May 11, 2026 to 10,831,187 after the assumed full sale of Common Units, before any warrant exercises. Sunshine Biopharma operates a generic drugs business in Canada and is developing oncology and antiviral candidates, including a liver cancer mRNA therapy and a coronavirus protease inhibitor.
NATAN DAVID reported acquisition or exercise transactions in this Form 4 filing.
Sunshine Biopharma Inc. director Natan David received a stock award of 100,000 shares of Common Stock. The shares were granted at a price of $0.00 per share as compensation, not through an open-market purchase. Following this grant, he directly holds 100,000 shares.
Sunshine Biopharma Inc. reported 2025 revenue of $36.3 million, a 4.1% increase from 2024, as it expanded its generic drug portfolio and advanced proprietary R&D programs. Gross profit rose to $12.26 million, while general and administrative expenses increased to $18.48 million, including a non-cash, non-recurring $1.75 million impairment charge on intangible assets.
The company recorded a net loss of $5.98 million for 2025, slightly higher than 2024. It raised $2.46 million in gross proceeds through a registered direct offering to support sales expansion and launched nine new generic prescription drugs. Management implemented cost-reduction initiatives in January 2026, which are expected to lower expenses by about $2 million to $3 million in 2026 as it works toward near-term profitability.
Sunshine Biopharma Inc. reported 2025 revenue of $36,305,891, up from $34,874,283 in 2024, driven mainly by expanded Canadian generic drug sales through its Nora Pharma subsidiary. Cost of sales was $24,050,214, yielding gross profit of $12,255,677.
The company remains unprofitable, recording a 2025 net loss of $5,975,352 and an accumulated deficit of $75,015,126, though operating cash use declined versus 2024. Sunshine ended 2025 with $9,123,308 in cash and believes this will fund operations for about 18 months. Its portfolio includes 71 generic drugs in Canada, 22 pipeline generics, OTC supplements, and two proprietary programs (K1.1 mRNA for liver cancer and SBFM-PL4, a PLpro inhibitor for SARS coronavirus) in animal testing. In December 2025 it received a USPTO Notice of Allowance for its coronavirus protease inhibitor patent, and it holds trademarks for “Sunshine Biopharma Inc.” in the U.S. and Canada.